Kaposi's sarcoma-associated herpesvirus-encoded replication and transcription activator impairs innate immunity via ubiquitin-mediated degradation of myeloid differentiation factor 88

Journal of Virology

Volumn 89, Issue 1, 2015, Pages 415-427

  Zhao, Qinglan ^a   Liang, Deguang ^a   Sun, Rui ^a   Jia, Baosen ^a   Xia, Tian ^a   Xiao, Hui ^a   Lan, Ke ^a  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; LIPOPOLYSACCHARIDE; MYELOID DIFFERENTIATION FACTOR 88; PROTEASOME; REPLICATION AND TRANSCRIPTION ACTIVATOR; RNA; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; MYD88 PROTEIN, HUMAN; ORF 50 TRANSACTIVATOR; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; GENE; GENETIC TRANSCRIPTION; HERPES SIMPLEX; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LANA 1 GENE; NONHUMAN; PLASMID; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; UBIQUITINATION; VIRUS REACTIVATION; WESTERN BLOTTING; CELL LINE; HOST PATHOGEN INTERACTION; IMMUNE EVASION; IMMUNOLOGY; METABOLISM; PROTEIN ANALYSIS;

HUMAN HERPESVIRUS 8;

CELL LINE; HERPESVIRUS 8, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN INTERACTION MAPPING; PROTEOLYSIS; TRANS-ACTIVATORS; UBIQUITIN;

EID: 84919419114     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02591-14     Document Type: Article

References (75)

1. Kawai T, Akira S. 2009. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 21:317-337. http://dx.doi.org/10.1093/intimm/dxp017.
2. Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR, Latz E, Fitzgerald KA. 2009. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458:514-518. http://dx.doi.org/10.1038/nature07725.
3. Yanai H, Savitsky D, Tamura T, Taniguchi T. 2009. Regulation of the cytosolic DNA-sensing system in innate immunity: a current view. Curr Opin Immunol 21:17-22. http://dx.doi.org/10.1016/j.coi.2009.01.005.
4. Janeway CA, Jr. 1992. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today 13:11-16. http://dx.doi.org/10.1016/0167-5699(92)90198-G.
5. Dolganiuc A, Oak S, Kodys K, Golenbock DT, Finberg RW, Kurt-Jones E, Szabo G. 2004. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 127:1513-1524. http://dx.doi.org/10.1053/j.gastro.2004.08.067.
6. Bowie AG, Unterholzner L. 2008. Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol 8:911-922. http://dx.doi.org/10.1038/nri2436.
7. Sorensen LN, Reinert LS, Malmgaard L, Bartholdy C, Thomsen AR, Paludan SR. 2008. TLR2 and TLR9 synergistically control herpes simplex virus infection in the brain. J Immunol 181:8604-8612. http://dx.doi.org/10.4049/jimmunol.181.12.8604.
8. Zhou S, Halle A, Kurt-Jones EA, Cerny AM, Porpiglia E, Rogers M, Golenbock DT, Finberg RW. 2008. Lymphocytic choriomeningitis virus (LCMV) infection of CNS glial cells results in TLR2-MyD88/Maldependent inflammatory responses. J Neuroimmunol 194:70-82. http://dx.doi.org/10.1016/j.jneuroim.2007.11.018.
9. Gaudreault E, Fiola S, Olivier M, Gosselin J. 2007. Epstein-Barr virus induces MCP-1 secretion by human monocytes via TLR2. J Virol 81: 8016-8024. http://dx.doi.org/10.1128/JVI.00403-07.
10. Aravalli RN, Hu S, Lokensgard JR. 2008. Inhibition of toll-like receptor signaling in primary murine microglia. J Neuroimmune Pharmacol 3:5-11. http://dx.doi.org/10.1007/s11481-007-9097-8.
11. Juckem LK, Boehme KW, Feire AL, Compton T. 2008. Differential initiation of innate immune responses induced by human cytomegalovirus entry into fibroblast cells. J Immunol 180:4965-4977. http://dx.doi.org/10.4049/jimmunol.180.7.4965.
12. Murawski MR, Bowen GN, Cerny AM, Anderson LJ, Haynes LM, Tripp RA, Kurt-Jones EA, Finberg RW. 2009. Respiratory syncytial virus activates innate immunity through Toll-like receptor 2. J Virol 83:1492-1500. http://dx.doi.org/10.1128/JVI.00671-08.
13. Barbalat R, Lau L, Locksley RM, Barton GM. 2009. Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands. Nat Immunol 10:1200-1207. http://dx.doi.org/10.1038/ni.1792.
14. Boehme KW, Guerrero M, Compton T. 2006. Human cytomegalovirus envelope glycoproteins B and H are necessary for TLR2 activation in permissive cells. J Immunol 177:7094-7102. http://dx.doi.org/10.4049/jimmunol.177.10.7094.
15. O'Neill LA, Bowie AG. 2007. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 7:353-364. http://dx.doi.org/10.1038/nri2079.
16. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, Janeway CA, Jr. 1998. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 2:253-258. http://dx.doi.org/10.1016/S1097-2765(00)80136-7.
17. Muzio M, Natoli G, Saccani S, Levrero M, Mantovani A. 1998. The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptorassociated factor 6 (TRAF6). J Exp Med 187:2097-2101. http://dx.doi.org/10.1084/jem.187.12.2097.
18. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S. 1999. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11:115-122. http://dx.doi.org/10.1016/S1074-7613(00)80086-2.
19. Takeuchi O, Takeda K, Hoshino K, Adachi O, Ogawa T, Akira S. 2000. Cellular responses to bacterial cell wall components are mediated through MyD88-dependent signaling cascades. Int Immunol 12:113-117. http://dx.doi.org/10.1093/intimm/12.1.113.
20. Edelson BT, Unanue ER. 2002. MyD88-dependent but Toll-like receptor 2-independent innate immunity to Listeria: no role for either in macrophage listericidal activity. J Immunol 169:3869-3875. http://dx.doi.org/10.4049/jimmunol.169.7.3869.
21. Takeuchi O, Hoshino K, Akira S. 2000. Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol 165:5392-5396. http://dx.doi.org/10.4049/jimmunol.165.10.5392.
22. Scanga CA, Aliberti J, Jankovic D, Tilloy F, Bennouna S, Denkers EY, Medzhitov R, Sher A. 2002. Cutting edge: MyD88 is required for resistance to Toxoplasma gondii infection and regulates parasite-induced IL-12 production by dendritic cells. J Immunol 168:5997-6001. http://dx.doi.org/10.4049/jimmunol.168.12.5997.
23. Hemmi H, Kaisho T, Takeda K, Akira S. 2003. The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. J Immunol 170:3059-3064. http://dx.doi.org/10.4049/jimmunol.170.6.3059.
24. Takeda K, Akira S. 2005. Toll-like receptors in innate immunity. Int Immunol 17:1-14. http://dx.doi.org/10.1093/intimm/dxh186.
25. Krug A, Luker GD, Barchet W, Leib DA, Akira S, Colonna M. 2004. Herpes simplex virus type 1 activates murine natural interferonproducing cells through toll-like receptor 9. Blood 103:1433-1437. http://dx.doi.org/10.1182/blood-2003-08-2674.
26. Honda K, Yanai H, Mizutani T, Negishi H, Shimada N, Suzuki N, Ohba Y, Takaoka A, Yeh WC, Taniguchi T. 2004. Role of a transductionaltranscriptional processor complex involving MyD88 and IRF-7 in Tolllike receptor signaling. Proc Natl Acad Sci USA 101:15416-15421. http://dx.doi.org/10.1073/pnas.0406933101.
27. Kawai T, Sato S, Ishii KJ, Coban C, Hemmi H, Yamamoto M, Terai K, Matsuda M, Inoue J, Uematsu S, Takeuchi O, Akira S. 2004. Interferonalpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol 5:1061-1068. http://dx.doi.org/10.1038/ni1118.
28. Honda K, Ohba Y, Yanai H, Negishi H, Mizutani T, Takaoka A, Taya C, Taniguchi T. 2005. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 434:1035-1040. http://dx.doi.org/10.1038/nature03547.
29. Li J, Lin S, Chen Q, Peng L, Zhai J, Liu Y, Yuan Z. 2010. Inhibition of hepatitis B virus replication by MyD88 involves accelerated degradation of pregenomic RNA and nuclear retention of pre-S/S RNAs. J Virol 84:6387-6399. http://dx.doi.org/10.1128/JVI.00236-10.
30. Szretter KJ, Daffis S, Patel J, Suthar MS, Klein RS, Gale M, Jr, Diamond MS. 2010. The innate immune adaptor molecule MyD88 restricts West Nile virus replication and spread in neurons of the central nervous system. J Virol 84:12125-12138. http://dx.doi.org/10.1128/JVI.01026-10.
31. Bhoj VG, Sun Q, Bhoj EJ, Somers C, Chen X, Torres JP, Mejias A, Gomez AM, Jafri H, Ramilo O, Chen ZJ. 2008. MAVS and MyD88 are essential for innate immunity but not cytotoxic T lymphocyte response against respiratory syncytial virus. Proc Natl Acad Sci USA 105:14046-14051. http://dx.doi.org/10.1073/pnas.0804717105.
32. Sheahan T, Morrison TE, Funkhouser W, Uematsu S, Akira S, Baric RS, Heise MT. 2008. MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog 4:e1000240. http://dx.doi.org/10.1371/journal.ppat.1000240.
33. Seo SU, Kwon HJ, Song JH, Byun YH, Seong BL, Kawai T, Akira S, Kweon MN. 2010. MyD88 signaling is indispensable for primary influenza A virus infection but dispensable for secondary infection. J Virol 84:12713-12722. http://dx.doi.org/10.1128/JVI.01675-10.
34. Zhao Y, De Trez C, Flynn R, Ware CF, Croft M, Salek-Ardakani S. 2009. The adaptor molecule MyD88 directly promotes CD8 T cell responses to vaccinia virus. J Immunol 182:6278-6286. http://dx.doi.org/10.4049/jimmunol.0803682.
35. Nicholls PK, Moore PF, Anderson DM, Moore RA, Parry NR, Gough GW, Stanley MA. 2001. Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes. Virology 283:31-39. http://dx.doi.org/10.1006/viro.2000.0789.
36. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-1869. http://dx.doi.org/10.1126/science.7997879.
37. Chang Y, Moore PS. 1996. Kaposi's sarcoma (KS)-associated herpesvirus and its role in KS. Infect Agents Dis 5:215-222.
38. West JT, Wood C. 2003. The role of Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8 regulator of transcription activation (RTA) in control of gene expression. Oncogene 22:5150-5163. http://dx.doi.org/10.1038/sj.onc.1206555.
39. Dourmishev LA, Dourmishev AL, Palmeri D, Schwartz RA, Lukac DM. 2003. Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis. Microbiol Mol Biol Rev 67:175-212. http://dx.doi.org/10.1128/MMBR.67.2.175-212.2003.
40. Sarid R, Flore O, Bohenzky RA, Chang Y, Moore PS. 1998. Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1). J Virol 72:1005-1012.
41. Krishnan HH, Naranatt PP, Smith MS, Zeng L, Bloomer C, Chandran B. 2004. Concurrent expression of latent and a limited number of lytic genes with immune modulation and antiapoptotic function by Kaposi's sarcomaassociated herpesvirus early during infection of primary endothelial and fibroblast cells and subsequent decline of lytic gene expression. J Virol 78:3601-3620. http://dx.doi.org/10.1128/JVI.78.7.3601-3620.2004.
42. Renne R, Lagunoff M, Zhong W, Ganem D. 1996. The size and conformation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) DNA in infected cells and virions. J Virol 70:8151-8154.
43. Russo JJ, Bohenzky RA, Chien MC, Chen J, Yan M, Maddalena D, Parry JP, Peruzzi D, Edelman IS, Chang Y, Moore PS. 1996. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci USA 93:14862-14867. http://dx.doi.org/10.1073/pnas.93.25.14862.
44. Sun R, Lin SF, Gradoville L, Miller G. 1996. Polyadenylylated nuclear RNA encoded by Kaposi sarcoma-associated herpesvirus. Proc Natl Acad Sci USA 93:11883-11888. http://dx.doi.org/10.1073/pnas.93.21.11883.
45. Cai X, Lu S, Zhang Z, Gonzalez CM, Damania B, Cullen BR. 2005. Kaposi's sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells. Proc Natl Acad Sci USA 102:5570-5575. http://dx.doi.org/10.1073/pnas.0408192102.
46. Xu Y, Ganem D. 2010. Making sense of antisense: seemingly noncoding RNAs antisense to the master regulator of Kaposi's sarcoma-associated herpesvirus lytic replication do not regulate that transcript but serve as mRNAs encoding small peptides. J Virol 84:5465-5475. http://dx.doi.org/10.1128/JVI.02705-09.
47. Rezaee SA, Cunningham C, Davison AJ, Blackbourn DJ. 2006. Kaposi's sarcoma-associated herpesvirus immune modulation: an overview. J Gen Virol 87:1781-1804. http://dx.doi.org/10.1099/vir.0.81919-0.
48. Sozzani S, Luini W, Bianchi G, Allavena P, Wells TN, Napolitano M, Bernardini G, Vecchi A, D'Ambrosio D, Mazzeo D, Sinigaglia F, Santoni A, Maggi E, Romagnani S, Mantovani A. 1998. The viral chemokine macrophage inflammatory protein-II is a selective Th2 chemoattractant. Blood 92:4036-4039.
49. Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F, Mattmann C, Burns K, Bodmer JL, Schroter M, Scaffidi C, Krammer PH, Peter ME, Tschopp J. 1997. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386:517-521. http://dx.doi.org/10.1038/386517a0.
50. Liang Q, Fu B, Wu F, Li X, Yuan Y, Zhu F. 2012. ORF45 of Kaposi's sarcoma-associated herpesvirus inhibits phosphorylation of interferon regulatory factor 7 by IKKepsilon and TBK1 as an alternative substrate. J Virol 86:10162-10172. http://dx.doi.org/10.1128/JVI.05224-11.
51. Zhu FX, King SM, Smith EJ, Levy DE, Yuan Y. 2002. A Kaposi's sarcoma-associated herpesviral protein inhibits virus-mediated induction of type I interferon by blocking IRF-7 phosphorylation and nuclear accumulation. Proc Natl Acad Sci USA 99:5573-5578. http://dx.doi.org/10.1073/pnas.082420599.
52. Lukac DM, Kirshner JR, Ganem D. 1999. Transcriptional activation by the product of open reading frame 50 of Kaposi's sarcoma-associated herpesvirus is required for lytic viral reactivation in B cells. J Virol 73:9348-9361.
53. Sun R, Lin SF, Gradoville L, Yuan Y, Zhu F, Miller G. 1998. A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci USA 95:10866-10871. http://dx.doi.org/10.1073/pnas.95.18.10866.
54. Bechtel JT, Winant RC, Ganem D. 2005. Host and viral proteins in the virion of Kaposi's sarcoma-associated herpesvirus. J Virol 79:4952-4964. http://dx.doi.org/10.1128/JVI.79.8.4952-4964.2005.
55. Lan K, Kuppers DA, Verma SC, Sharma N, Murakami M, Robertson ES. 2005. Induction of Kaposi's sarcoma-associated herpesvirus latencyassociated nuclear antigen by the lytic transactivator RTA: a novel mechanism for establishment of latency. J Virol 79:7453-7465. http://dx.doi.org/10.1128/JVI.79.12.7453-7465.2005.
56. Yu Y, Wang SE, Hayward GS. 2005. The KSHV immediate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-mediated degradation. Immunity 22:59-70. http://dx.doi.org/10.1016/j.immuni.2004.11.011.
57. Ahmad H, Gubbels R, Ehlers E, Meyer F, Waterbury T, Lin R, Zhang L. 2011. Kaposi sarcoma-associated herpesvirus degrades cellular Tollinterleukin-1 receptor domain-containing adaptor-inducing betainterferon (TRIF). J Biol Chem 286:7865-7872. http://dx.doi.org/10.1074/jbc.M110.191452.
58. Izumiya Y, Kobayashi K, Kim KY, Pochampalli M, Izumiya C, Shevchenko B, Wang DH, Huerta SB, Martinez A, Campbell M, Kung HJ. 2013. Kaposi's sarcoma-associated herpesvirus K-Rta exhibits SUMO-targeting ubiquitin ligase (STUbL) like activity and is essential for viral reactivation. PLoS Pathog 9:e1003506. http://dx.doi.org/10.1371/journal.ppat.1003506.
59. Lan K, Kuppers DA, Verma SC, Robertson ES. 2004. Kaposi's sarcomaassociated herpesvirus-encoded latency-associated nuclear antigen inhibits lytic replication by targeting Rta: a potential mechanism for virusmediated control of latency. J Virol 78:6585-6594. http://dx.doi.org/10.1128/JVI.78.12.6585-6594.2004.
60. Diao L, Zhang B, Fan J, Gao X, Sun S, Yang K, Xin D, Jin N, Geng Y, Wang C. 2005. Herpes virus proteins ICP0 and BICP0 can activate NFkappaB by catalyzing IkappaBalpha ubiquitination. Cell Signal 17:217-229. http://dx.doi.org/10.1016/j.cellsig.2004.07.003.
61. Myoung J, Ganem D. 2011. Infection of primary human tonsillar lymphoid cells by KSHV reveals frequent but abortive infection of T cells. Virology 413:1-11. http://dx.doi.org/10.1016/j.virol.2010.12.036.
62. Laney JD, Hochstrasser M. 2002. Analysis of protein ubiquitination. Curr Protoc Protein Sci Chapter 14:Unit 14.5. http://dx.doi.org/10.1002/0471140864.ps1405s29.
63. Sun R, Lin SF, Staskus K, Gradoville L, Grogan E, Haase A, Miller G. 1999. Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression. J Virol 73:2232-2242.
64. Zhu FX, Cusano T, Yuan Y. 1999. Identification of the immediate-early transcripts of Kaposi's sarcoma-associated herpesvirus. J Virol 73:5556-5567.
65. Abend JR, Ramalingam D, Kieffer-Kwon P, Uldrick TS, Yarchoan R, Ziegelbauer JM. 2012. Kaposi's sarcoma-associated herpesvirus microRNAs target IRAK1 and MYD88, two components of the toll-like receptor/interleukin-1R signaling cascade, to reduce inflammatory-cytokine expression. J Virol 86:11663-11674. http://dx.doi.org/10.1128/JVI.01147-12.
66. Lagos D, Vart RJ, Gratrix F, Westrop SJ, Emuss V, Wong PP, Robey R, Imami N, Bower M, Gotch F, Boshoff C. 2008. Toll-like receptor 4 mediates innate immunity to Kaposi sarcoma herpesvirus. Cell Host Microbe 4:470-483. http://dx.doi.org/10.1016/j.chom.2008.09.012.
67. West J, Damania B. 2008. Upregulation of the TLR3 pathway by Kaposi's sarcoma-associated herpesvirus during primary infection. J Virol 82: 5440-5449. http://dx.doi.org/10.1128/JVI.02590-07.
68. West JA, Gregory SM, Sivaraman V, Su L, Damania B. 2011. Activation of plasmacytoid dendritic cells by Kaposi's sarcoma-associated herpesvirus. J Virol 85:895-904. http://dx.doi.org/10.1128/JVI.01007-10.
69. Gregory SM, West JA, Dillon PJ, Hilscher C, Dittmer DP, Damania B. 2009. Toll-like receptor signaling controls reactivation of KSHV from latency. Proc Natl Acad Sci USA 106:11725-11730. http://dx.doi.org/10.1073/pnas.0905316106.
70. Abend JR, Ramalingam D, Kieffer-Kwon P, Uldrick TS, Yarchoan R, Ziegelbauer JM. 2012. Kaposi's sarcoma-associated herpesvirus microRNAs target IRAK1 and MYD88, two components of the toll-like receptor/interleukin-1R signaling cascade, to reduce inflammatory-cytokine expression. J Virol 86:11663-11674. http://dx.doi.org/10.1128/JVI.01147-12.
71. Lee YS, Park JS, Kim JH, Jung SM, Lee JY, Kim SJ, Park SH. 2011. Smad6-specific recruitment of Smurf E3 ligases mediates TGF-beta1-induced degradation of MyD88 in TLR4 signalling. Nat Commun 2:460. http://dx.doi.org/10.1038/ncomms1469.
72. Wang C, Chen T, Zhang J, Yang M, Li N, Xu X, Cao X. 2009. The E3 ubiquitin ligase Nrdp1 "preferentially" promotes TLR-mediated production of type I interferon. Nat Immunol 10:744-752. http://dx.doi.org/10.1038/ni.1742.
73. Puneet P, McGrath MA, Tay HK, Al-Riyami L, Rzepecka J, Moochhala SM, Pervaiz S, Harnett MM, Harnett W, Melendez AJ. 2011. The helminth product ES-62 protects against septic shock via Toll-like receptor 4-dependent autophagosomal degradation of the adaptor MyD88. Nat Immunol 12:344-351. http://dx.doi.org/10.1038/ni.2004.
74. van Lint AL, Murawski MR, Goodbody RE, Severa M, Fitzgerald KA, Finberg RW, Knipe DM, Kurt-Jones EA. 2010. Herpes simplex virus immediate-early ICP0 protein inhibits Toll-like receptor 2-dependent inflammatory responses and NF-kappaB signaling. J Virol 84:10802-10811. http://dx.doi.org/10.1128/JVI.00063-10.
75. Lin X, Li X, Liang D, Lan K. 2012. MicroRNAs and unusual small RNAs discovered in Kaposi's sarcoma-associated herpesvirus virions. J Virol 86: 12717-12730. http://dx.doi.org/10.1128/JVI.01473-12.